Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Restructuring (2020 - 2023)

Historic Cash from Restructuring for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 4 years, with Q1 2023 value amounting to $2.6 million.

  • Lifecore Biomedical, Inc. \De\'s Cash from Restructuring fell 5134.62% to $2.6 million in Q1 2023 from the same period last year, while for Feb 2023 it was $34.1 million, marking a year-over-year decrease of 1860.74%. This contributed to the annual value of $1.4 million for FY2024, which is 11906.25% up from last year.
  • As of Q1 2023, Lifecore Biomedical, Inc. \De\'s Cash from Restructuring stood at $2.6 million, which was down 5134.62% from $563000.0 recorded in Q4 2022.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Cash from Restructuring registered a high of $34.9 million during Q2 2021, and its lowest value of $563000.0 during Q4 2022.
  • Its 4-year average for Cash from Restructuring is $7.8 million, with a median of $2.1 million in 2021.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s Cash from Restructuring crashed by 8308.08% in 2021 and then skyrocketed by 15465.96% in 2022.
  • Quarter analysis of 4 years shows Lifecore Biomedical, Inc. \De\'s Cash from Restructuring stood at $1.1 million in 2020, then plummeted by 42.95% to $627000.0 in 2021, then fell by 10.21% to $563000.0 in 2022, then soared by 355.77% to $2.6 million in 2023.
  • Its last three reported values are $2.6 million in Q1 2023, $563000.0 for Q4 2022, and $1.0 million during Q3 2022.